GSK3772847

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 2

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

CompletedNCT03207243

GlaxoSmithKlineAsthma

Start: 2017-09-14End: 2019-05-15Updated: 2020-03-02

Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

TerminatedNCT03393806

GlaxoSmithKlineAsthma

Start: 2018-04-18End: 2020-01-06Updated: 2020-10-23

Related Papers

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

ERJ Open Research2023-08-0910 citations

Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial

PLoS ONE2023-02-0314 citations